Arika Carmel 2025: The operating improvement is real, but the cash cushion barely moved

Company Overview

Arika Carmel is no longer just a story about one home-use pain device. By the end of 2025 it looked more like a very small public company, with a market cap of about NIS 21.5 million as of April 6, 2026, trying to hold together two very different businesses: on one side B-Cure Laser, the legacy medical-device platform; on the other side a widening beauty and hair-removal distribution portfolio that keeps moving between buy-sell economics and commission economics. This is no longer a one-product company, but it is also not yet a clean consumer platform.

What is working now is Israel. Domestic revenue rose to NIS 35.8 million, operating loss narrowed to NIS 5.2 million from NIS 9.9 million in 2024, and operating cash flow turned positive at NIS 1.4 million. Those are real operating improvements. The company cut advertising, lowered overhead, and shifted the center of gravity toward the one market where it still knows how to sell.

What is still unresolved is the cash bottleneck. Cash and cash equivalents rose to NIS 3.9 million from NIS 1.8 million, but short-term financial assets fell to NIS 0.26 million from NIS 2.36 million. In other words, the visible cash balance improved largely because the company used its short-term securities portfolio and released working capital, not because the business suddenly began producing a deep cash surplus.

That is the active bottleneck. Arika has improved operationally, but it still has not shown that the improvement can fund itself without relying on working-capital release, deferred payments, and shifting commercial structures in the beauty portfolio. Add to that a trading volume of only NIS 220 on April 6, 2026, and the practical screen changes immediately. Even if the story improves, actionability remains weak.

At the end of 2025 the company had 46 employees. That implies revenue of roughly NIS 0.81 million per employee. This is reasonable for a small sales-and-distribution platform, but it does not look like the economics of a lean, already-scaled medtech engine. The right primary lens here is commercialization and distribution, not a medical-device growth platform that has already broken through abroad.

Events And Triggers

Israel has become almost the whole business

First trigger: by the end of 2025 Israel accounted for 96% of revenue, versus 82% in 2024. Europe fell to NIS 1.53 million from NIS 5.35 million, and North America was essentially gone. That reshapes the story. Arika should not currently be read as an international expansion company. It should be read as an Israeli sales platform with a still-unproven foreign option.

This cuts both ways. Israel gives the company a real sales base and supports narrower losses. But it also exposes the limit of the current thesis. A company that once framed foreign markets as the growth path has effectively fallen back on its domestic market. Any renewed overseas narrative should therefore be treated as optionality, not as current operating proof.

The beauty axis is expanding, but the economics are still moving

Second trigger: over the last two years the company has built a broader beauty and hair-removal layer around B-Cure. Epilady entered in 2024, Empire Tech in early 2025, iSmooth in December 2025, and YA-MAN began commercial activity in March 2026. That helps explain why the hair-removal and beauty bucket rose to NIS 7.4 million in 2025 from NIS 3.9 million in 2024.

But the economic model underneath those brands did not stay constant. During July 2025 one supplier arrangement shifted from a buy-sell model to a commission-only model, so part of the activity moved from revenue from sales to commission income. In 2025 the company already recorded NIS 2.0 million in commission income. Then, after the balance-sheet date, from February 2026, at least part of that beauty activity moved back to an inventory purchase-and-resale model. That makes 2025 less comparable than it first appears. Revenue, gross margin, and working capital were all affected by those model shifts.

The Barzilai study changes the FDA narrative, not yet the income statement

Third trigger: in January 2026 the company reported positive initial findings from a controlled clinical study at Barzilai Medical Center, and management decided to base the FDA path on that study rather than on an earlier one. For a company like Arika, any credible movement on the FDA track can change how investors read the foreign optionality.

Still, it needs to be sized correctly. There is no approval yet, no U.S. commercial traction, and no revenue contribution. This is a strategic trigger, not yet an operating engine.

The placement is small, but it tells a large story

Fourth trigger: in March 2026 the company signed a NIS 2.5 million investment agreement for about 9.6% of the equity at 22.6 agorot per share. The amount matters, but the terms matter just as much. The lead investor is expected to join the board, the investors get participation rights in the next private placement at 90% of that future price, and completion depends in part on a capital consolidation.

So this is not capital arriving from a position of strength. It is financing that still sits at the center of the story, and the price is paid both in the equity layer and in governance.

Efficiency, Profitability And Competition

The operating improvement is real, but it needs to be unpacked properly

The key 2025 data point is not growth. It is the structure of the improvement. Revenue slipped only 1.6% to NIS 37.3 million, while operating loss was cut almost in half. What drove that? Mainly a sharp drop in advertising and marketing spend to NIS 7.9 million from NIS 11.0 million, together with lower G&A at NIS 9.3 million versus NIS 11.4 million. That is a genuine improvement, and it shows management is no longer chasing top line at any cost.

But profitability is still not clean. Gross margin improved to 69.3% from 68.6%, which looks encouraging. The problem is that part of the business moved to a commission model during the year, lowering reported revenue without carrying the full cost of goods sold. So the gross-margin improvement is real only in part. It is not false, but it is not a pure read on underlying operating quality either.

There is also a one-off burden in 2025. The company booked NIS 753 thousand for a National Insurance payroll review covering 2018 through 2022. That weighed on operating loss. Excluding that item, operating loss would have been closer to NIS 4.5 million. So the underlying trend is somewhat better than the reported number. But even that does not solve the structural issue: the business is still loss-making.

The second half exposed the gap between gross margin optics and full economics

The second half of 2025 sharpened the point. Revenue fell to NIS 16.6 million from NIS 20.8 million in the first half, yet gross profit edged up to NIS 13.2 million from NIS 12.6 million. On first read that can look like a strong mix upgrade. In practice, operating loss widened to NIS 3.6 million from NIS 1.6 million.

That is the core of the story. When a business shifts toward commissions or other lighter reported structures, gross margin can look better very quickly. But if payroll, service, store costs, logistics, and public-company overhead do not fall at the same pace, the operating loss remains. Arika has therefore not yet proved that the beauty layer creates operating leverage. What it has proved is that reported gross margin can improve faster than the full economics.

Competition is heavier in beauty than in the medical core

In pain treatment, B-Cure still has some real assets: brand recognition, intellectual property, studies, and a degree of product differentiation versus other home-use alternatives. It is not a deep moat, but it is also not a pure commodity story.

Beauty looks different. That business sits inside a crowded branded market, with stronger dependence on marketing execution and customer acquisition, and far less proprietary advantage owned by Arika itself. Put simply, the beauty pivot helps volume and expands the catalog, but it also pulls the company toward the economics of distribution and consumer retail, where pricing power is usually weaker and marketing intensity can come back fast.

Cash Flow, Debt And Capital Structure

The right cash framing here is all-in cash flexibility, not normalized cash generation. The reason is simple. In a company this small, when the real question is how much room is left before the next proof point, the relevant frame is cash left after actual uses, not a narrower theoretical earnings-power bridge.

Positive operating cash flow did not really rebuild the liquidity buffer

Operating cash flow turned positive at NIS 1.4 million, versus negative NIS 4.2 million in 2024. That matters. But what created it? Mainly a NIS 2.8 million decline in receivables and a NIS 2.6 million decline in inventory, together with depreciation and amortization. In other words, 2025 looks more like a balance-sheet release year than a year of deep self-funded cash generation.

This is where a superficial read goes wrong. Cash went up, but cash plus short-term investments was basically flat at roughly NIS 4.1 million in both years. So the real picture is not “the cushion grew.” The real picture is “liquidity was reshuffled into cash while working capital was pulled down.”

There is no bank debt, but there is still financed inventory and supplier dependence

One positive point is that by year end the company had no bank financing left. That removes one layer of lender pressure. But no bank debt should not be confused with a comfortable balance sheet. Arika still relies heavily on supplier credit, which stood at NIS 9.6 million at year end, versus customer credit of NIS 3.6 million.

More importantly, the filing includes a meaningful disclosure on the Chinese manufacturer arrangement. The company had previously agreed to repay roughly $1.28 million related to components and finished goods ordered earlier and held by the manufacturer, with 5% annual interest and storage costs. At December 31, 2025, the balance still stood at about $0.8 million, and in October 2025 the parties agreed on monthly payments of $10,000. So part of the 2025 cash-flow improvement still sits on top of already-financed inventory that continues to require cash.

Related parties remain part of the solution, which also makes them part of the risk

Arika is not operating with a clean standalone balance sheet. At the end of 2025 it had current and non-current receivables from a company controlled by the controlling shareholder totaling NIS 2.6 million, while payables to that related-party layer were NIS 1.9 million. At the same time, the company still owed about NIS 1.1 million to the controlling shareholder for deferred salary reductions and adaptation payments.

This does not mean the numbers are wrong. It does mean the liquidity runway still depends partly on shareholder patience, offsets, and related-party commercial arrangements. For a microcap public company, that creates a meaningful gap between operating value and value that is freely accessible to outside shareholders.

Lease cash is also not trivial. Total lease cash outflow was NIS 1.49 million in 2025, and total lease liabilities stood at NIS 2.53 million. That is not fatal, but it is also not a side issue for a company whose immediate liquid resources sit around NIS 4.1 million.

Outlook

Before getting into detail, four non-obvious findings matter most:

1. Cash flow improved, but liquidity did not really widen. The short-term securities portfolio was largely consumed.
2. The 2025 gross-margin read is not fully clean. A shift toward commission income makes the reported mix look better without yet proving stronger operating leverage.
3. Israel is now almost the whole business. Overseas recovery remains more claim than result.
4. Financing still sets the pace. The March 2026 placement is materially important relative to the existing cash base.

That leads to the right label for 2026: this is a proof year, not a breakout year. The company needs to show that the beauty layer can evolve from a top-line support story into a true gross-profit and cash engine, without putting the pressure straight back into inventory, marketing, and working capital.

The first test is the new beauty model. After part of 2025 was reported through commissions, from February 2026 the company again purchases and resells at least part of the products as inventory. That should make the P&L easier to read, but it can also bring back working-capital strain very quickly. If the next growth phase comes with heavier inventory and weaker cash conversion, the 2025 improvement will look more temporary than structural.

The second test is B-Cure itself. The pain-treatment core still generated NIS 23.7 million of revenue, but stability in Israel is not enough. The company needs a real foreign proof point, commercial or regulatory, rather than another promised path. The Barzilai findings and the FDA decision tree matter, but without a measurable milestone they remain option value.

The third test is financing. If the private placement closes and meaningfully extends runway without triggering a chain of additional discounted raises, then the company will have bought real time. If not, the pressure returns fast, especially given the weak trading liquidity, the Chinese supplier overhang, and the company’s dependence on related-party deferrals.

So the right forward checklist is simple. To improve the read over the next 2 to 4 quarters, Arika needs to deliver three proofs at once: cash proof, model proof, and regulatory proof. Without all three, any single improvement will remain incomplete.

Risks

Liquidity risk is still alive

The company explicitly states that its ability to continue operating and meet obligations in the foreseeable future depends on management’s plan and on meeting its cash-flow forecast. The external auditor drew explicit attention to that disclosure. This is not a dramatic collapse case, but it is also not a company that has clearly moved beyond liquidity risk.

The problem is not only the loss level. It is the width of the buffer. Arika has very little room for mistakes. Any uncontrolled rebuild in inventory, any delay on the FDA track, any failure to close the placement, or any worsening of the regulatory noise can bring the story back to emergency funding rather than operating progress.

Regulatory and legal overhang is still part of the equity story

This is one of the heavier yellow flags. The company already carried a NIS 1.5 million provision related to the Securities Authority administrative enforcement process. Beyond that, there is a conditional fine, an external checker for one year, a pending administrative appeal, and a separate administrative review regarding errors in the 2021 and 2022 financial statements. There is also a class-action track, a derivative track, and the former CEO lawsuit.

The point is not only the immediate cash exposure. The larger issue is trust discount. In a tiny public company with weak liquidity and recurring funding needs, governance and regulatory noise are not background conditions. They are part of the valuation.

The supply chain still runs through one key node

The company remains dependent on a single Chinese manufacturer for the B-Cure core, and part of the regulatory architecture around the product is tied to that manufacturer. The filing itself treats that dependence as a material risk. So even if demand stabilizes, any production disruption, commercial dispute, or approval-maintenance problem can raise business risk very quickly.

Currency exposure also matters

The company says pound exposure is no longer material, but U.S. dollar exposure still is. It also states that a weaker shekel versus the dollar can hurt operating profitability, while management only says it is considering hedging rather than describing an active hedge program. For an importer that still depends on a Chinese producer and dollar-linked obligations, that point should remain open.

Conclusions

The Arika story improved in 2025, but it did not become clean. There is real operating progress, a move to positive operating cash flow, and a stronger Israeli revenue base. At the same time, the liquidity cushion barely widened, overseas activity has not come back, and the business still leans on working-capital release, deferrals, and financing support.

What will drive the market read over the short to medium term is not another quarter with a pretty gross margin. It is whether 2026 proves that the new beauty model can generate real cash, whether the financing layer closes cleanly, and whether the medical core produces a measurable regulatory milestone.

Current thesis: Arika no longer looks like a business in free fall, but it still has not proved it is out of survival mode.

What changed from the prior read: 2025 brought genuine efficiency gains, a much smaller operating loss, and positive operating cash flow, but it also showed that the improvement still depends more on balance-sheet release and changing commercial models than on a rebuilt cash buffer.

Counter thesis: A reasonable opposing case is that the company has already passed the trough, that new brands are broadening the sales base, and that the Barzilai study, new investment, and continued cost discipline are enough to extend runway without another painful funding round.

What could change the market interpretation: closing the private placement, proving that the new brands can generate gross profit and cash under the renewed purchase-and-resale model, and delivering a measurable FDA-related milestone.

Why this matters: in a company of this size, the gap between a smaller operating loss and a business that can genuinely fund itself is the entire story.

What must happen over the next 2 to 4 quarters: cash needs to stop depending on working-capital release, the beauty portfolio needs to prove durable economics, and the company needs to pass both the financing and regulatory tests without another harsher dilution event. What would weaken the thesis is a return to inventory pressure, more dilution, or a new break in the trust layer.